Ciro Celsa
27PUBLICATIONS
119CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (27)
Sort by Publication Date:
|Jan 28, 2026
Role of Liver Function in the Multiparametric Assessment of Hepatocellular Carcinoma.Fabio Melandro, Leonardo Centonze, Ciro Celsa
|Feb 27, 2025
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies.Ciro Celsa, Grazia Pennisi, Adele Tulone
|Dec 26, 2024
Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.Ciro Celsa, Giuseppe Cabibbo, David J Pinato
|Nov 22, 2024
Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death.Giuseppe Cabibbo, Ciro Celsa, Salvatore Battaglia
|Aug 29, 2024
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis.Ciro Celsa, Giacomo E M Rizzo, Gabriele Di Maria
|Jul 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi
Pageof 5
Frequent Collaborators
13 joint publications
Giuseppe Cabibbo
7 joint publications
Calogero Cammà
4 joint publications
Fabio Marra
4 joint publications
Paolo Giuffrida
4 joint publications
Roberto Cannella
4 joint publications
Giacomo Emanuele Maria Rizzo
4 joint publications
David James Pinato
3 joint publications
Franco Trevisani
3 joint publications
Marco Enea
3 joint publications
Francesco Paolo Russo
